We recently updated our Privacy Notice and Terms of Use.
Med-IQ
<i>Medical Insiders:</i> Evolving Evidence for the Role of SGLT Inhibition in Type 1 Diabetes Management
Webcast Webcast

Medical Insiders: Evolving Evidence for the Role of SGLT Inhibition in Type 1 Diabetes Management


Released:
11/30/18
Expires:
11/29/19
PDF:

Maximum Credits:

0.75
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Webcast Webcast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
11/30/18

Expires:
11/29/19

PDF:

Maximum Credits:
0.75
Webcast Webcast
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
11/30/18
Expires:
11/29/19
PDF:


Maximum Credits:
0.75


Overview: In this accredited CME webcast, experts review the physiologic role of sodium-glucose cotransporter (SGLT) 1 and 2, as well as their inhibition, and the effect of inhibitors on glucose homeostasis in patients with type 1 diabetes mellitus (T1DM). Key discussions include results of a nationally fielded practice assessment survey, which evaluated current trends and perceptions regarding the use of SGLT inhibitors in those with T1DM, as well as key clinical trial data regarding the efficacy and safety of using SGLT2 or SGLT1/2 inhibitors in this patient population.

CME Information:

Faculty
John B. Buse, MD, PhD - Chair
Verne S. Caviness Distinguished Professor
Chief, Division of Endocrinology
Director, Diabetes Center
Director, NC Translational and Clinical Sciences Institute
Executive Associate Dean, Clinical Research
University of North Carolina School of Medicine
Chapel Hill, NC

Thomas Lynch O’Connell, MD, FACE
Endocrinology, Diabetes and Metabolism Division
Duke Health, Kernodle Clinic
Burlington, NC

Wendy S. Lane, MD
Mountain Diabetes & Endocrine Center
Asheville, NC

Activity Planners
Erin Grothey, MS
Clinical Content Manager
Med-IQ
Baltimore, MD

Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI
 
Learning Objectives
Upon completion, participants should be able to:

  • Recognize the rationale for using SGLT1 and SGLT2 inhibitors for the management of hyperglycemia in patients with T1DM
  • Evaluate the safety and efficacy data regarding the use of SGLT inhibitors in combination with insulin for the management of T1DM

Target Audience
This activity is intended for endocrinologists and endocrinology-focused nurse practitioners and physician assistants.

Statement of Need
Despite critical advances in insulin formulations, delivery methods, and monitoring approaches, control of hyperglycemia in patients with type 1 diabetes mellitus (T1DM) remains suboptimal. In an effort to minimize the risk of severe hypoglycemia or obesity, these patients often choose to maintain a degree of hyperglycemia, which in turn puts them at risk of developing related complications. Providers are increasingly exploring the possibility of prescribing add-on therapy to existing insulin treatment in patients with T1DM. Although sodium-glucose cotransporter (SGLT) 2 inhibitors have been approved for use in patients with type 2 diabetes mellitus for some time, the use of this drug class in patients with T1DM is currently off-label. Endocrinologists and endocrinology-focused advanced care practitioners would benefit from expert insight regarding results of recent phase 3 clinical trials investigating the use of SGLT2 and SGLT1/2 inhibitors in this patient population, as well as guidance about how to discuss with patients the benefits and potential harms of SGLT inhibition.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses, nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
 
Instructions to Receive Credit
To receive credit, read the introductory CME material, watch the webcast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: November 30, 2018
Expiration Date: November 29, 2019
Estimated Time to Complete This Activity: 45 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

John B. Buse, MD, PhD
Contracted research: Neurimmune
Ownership interest (stocks/stock options – excluding mutual funds): Mellitus Health, PhaseBio Pharmaceuticals, Inc.

Thomas Lynch O’Connell, MD, FACE
Fees received for promotional/non-CME activities: AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk, Sanofi-aventis U.S. Inc.

Wendy S. Lane, MD
Consulting fees/advisory boards: Insulet Corporation, Novo Nordisk, Sanofi-aventis U.S. Inc.
Contracted research: Dexcom, Inc., Novo Nordisk, Sanofi-aventis U.S. Inc.
Other (speakers bureau): Dexcom, Inc., Insulet Corporation, Novo Nordisk

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email info@med-iq.com.
                     
System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-policy.html.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Sanofi US and Lexicon Pharmaceuticals, Inc.

Copyright
© 2018 Med-IQ, Inc.
 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.